【翰宇药业:全资子公司替尔泊肽原料药获韩国MFDS受理】翰宇药业公告,全资子公司翰宇药业(武汉)有限公司的替尔泊肽原料药获得韩国食品药品安全厅(MFDS)的审批受理。替尔泊肽是一种新型GLP-1/GIP双受体激动剂,适用于2型糖尿病、肥胖症等治疗。该药品的受理将完善公司产品版图,提升公司竞争力,有望对公司业绩增长和行业地位产生积极影响。

金融界
18 Apr
翰宇药业公告,全资子公司翰宇药业(武汉)有限公司的替尔泊肽原料药获得韩国食品药品安全厅(MFDS)的审批受理。替尔泊肽是一种新型GLP-1/GIP双受体激动剂,适用于2型糖尿病、肥胖症等治疗。该药品的受理将完善公司产品版图,提升公司竞争力,有望对公司业绩增长和行业地位产生积极影响。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10